Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Friday, January 8, 2010

Biogen to reinstate monthly PML updates

Friday, January 08, 2010

BIOGEN IDEC – the Boston-based pharmaceutical firm which co-owns the Tysabri multiple sclerosis drug with Athlone-based Elan – is set to re-instate monthly updates of outbreaks of PML, the rare brain disease which is a potential side effect of using Tysabri, after announcing four further cases of the condition.

The four new instances of PML were developed by Tysabri users in the US during November and bring the total number of outbreaks amongst users of the treatment to 28. Biogen recently ceased updating on new PML cases on its website, but is likely to release data for December before the end of this month.

CLICK to Read more


Keep Informed with News and Information regarding Multiple Sclerosis. If not yet receiving the "Stu's Views and MS Related News", weekly M.S. e-newsletter, then please take 20 seconds to register at: . - Thank you


1 comment:

Anonymous said...

As quoted in the update:
"About 46,200 patients were on commercial and clinical Tysabri therapy worldwide at the end of the third quarter of 2009. This represents an increase from the 43,300 patients reported by the company in the second quarter of 2009".
To me this means the ratio will increase.